Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Stockholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / March 26, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ:IBRX). Investors who purchased ImmunityBio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IBRX.

ImmunityBio Investigation Details

On March 24, 2026, Reuters published an article entitled "ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad." The article stated that ImmunityBio shares fell after "the U.S. Food and Drug Administration issued &zwnj;a warning letter that said a television advertisement and podcast promoting the company's cancer therapy were false or misleading and violated federal law." Following this news, ImmunityBio's stock price dropped 21% that same day.

What's Next for ImmunityBio Investors?

If you are aware of any facts relating to this investigation or purchased ImmunityBio securities, you can assist this investigation by visiting the firm's site: bgandg.com/IBRX. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to ImmunityBio Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for ImmunityBio Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View the original press release on ACCESS Newswire

COMTEX_476000351/2457/2026-03-26T11:24:36